• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    New Drug Application (NDA): 022192
    Company: VANDA PHARMS INC
    • Email
    • Other Important Information from FDA
    • Summary Review

    Products on NDA 022192

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    FANAPT ILOPERIDONE 1MG TABLET;ORAL Prescription AB Yes Yes
    FANAPT ILOPERIDONE 2MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 4MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 6MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 8MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 10MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 12MG TABLET;ORAL Prescription AB Yes No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 022192

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/06/2009 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD Label (PDF)
    Letter (PDF)
    Review
    Summary Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022192s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    04/02/2024 SUPPL-23 Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022192s023lbl.pdf
    02/23/2017 SUPPL-21 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022192Orig1s018,s021ltr.pdf
    01/06/2017 SUPPL-20 Manufacturing (CMC)

    Label is not available on this site.

    02/23/2017 SUPPL-18 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022192Orig1s018,s021ltr.pdf
    01/05/2016 SUPPL-17 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022192Orig1s017ltr.pdf
    03/29/2016 SUPPL-16 Manufacturing (CMC)

    Label is not available on this site.

    05/26/2016 SUPPL-15 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022192Orig1s015ltr.pdf
    03/30/2015 SUPPL-14 Manufacturing (CMC)

    Label is not available on this site.

    04/21/2014 SUPPL-13 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022192s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022192Orig1s013ltr.pdf
    07/19/2013 SUPPL-12 Manufacturing (CMC)

    Label is not available on this site.

    05/30/2013 SUPPL-11 Manufacturing (CMC)

    Label is not available on this site.

    07/12/2013 SUPPL-10 Manufacturing (CMC)

    Label is not available on this site.

    01/27/2012 SUPPL-9 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022192s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022192s009ltr.pdf
    01/31/2013 SUPPL-7 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022192s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022192Orig1s007ltr.pdf
    09/07/2011 SUPPL-6 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022192s005,s006ltr.pdf
    09/07/2011 SUPPL-5 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022192s005,s006ltr.pdf
    03/21/2011 SUPPL-4 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022192s004ltr.pdf
    12/01/2010 SUPPL-2 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022192s002ltr.pdf
    08/24/2010 SUPPL-1 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022192s001ltr.pdf

    Labels for NDA 022192

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    04/02/2024 SUPPL-23 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022192s023lbl.pdf
    02/23/2017 SUPPL-21 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
    02/23/2017 SUPPL-18 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
    05/26/2016 SUPPL-15 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s015lbl.pdf
    01/05/2016 SUPPL-17 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s017lbl.pdf
    04/21/2014 SUPPL-13 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022192s013lbl.pdf
    01/31/2013 SUPPL-7 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022192s007lbl.pdf
    01/27/2012 SUPPL-9 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022192s009lbl.pdf
    09/07/2011 SUPPL-6 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf
    09/07/2011 SUPPL-5 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf
    03/21/2011 SUPPL-4 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s004lbl.pdf
    12/01/2010 SUPPL-2 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s002lbl.pdf
    08/24/2010 SUPPL-1 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s001lbl.pdf
    05/06/2009 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf

    Therapeutic Equivalents for NDA 022192

    FANAPT

    TABLET;ORAL; 1MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 1MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 2MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 2MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 4MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 4MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 6MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 6MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 8MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 8MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 10MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 10MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 12MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 12MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC
    Get the next $VNDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    11/5/2025$11.00Buy
    B. Riley Securities
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

    H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    10/31/24 6:31:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00

    7/11/24 7:49:37 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

    WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City on Wednesday, November 12, 2025. A corporate presentation is scheduled for 4:40 p.m. Eastern Time. The corporate presentation given at the Stifel conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the links under Recent Events. Investors are advised to go to the conference websites at least 15 mi

    11/5/25 5:00:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in Q4 2025Vanda announced collaborative framework with the FDA for resolution of certain disputesRe-review of Vanda's sNDA for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today an

    10/29/25 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    SEC Filings

    View All

    SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

    10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    10/30/25 7:23:10 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    10/29/25 4:08:14 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    10/1/25 5:10:10 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/16/25 9:10:04 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/9/25 5:36:16 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/21/25 9:23:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/19/25 5:13:38 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in Q4 2025Vanda announced collaborative framework with the FDA for resolution of certain disputesRe-review of Vanda's sNDA for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today an

    10/29/25 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.

    7/31/25 7:30:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 5:16:07 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 10:53:14 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/9/24 9:59:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Leadership Updates

    Live Leadership Updates

    View All

    Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

    WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

    3/17/23 7:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care